Publicaciones en las que colabora con María Dolores Martín Arranz (30)

2024

  1. Intensification with Intravenous Ustekinumab in Refractory Crohn’s Disease

    Journal of Clinical Medicine, Vol. 13, Núm. 3

  2. Selective granulocyte–monocyte apheresis during induction with vedolizumab in moderate–severe ulcerative colitis: Experience in a tertiary hospital

    Gastroenterologia y Hepatologia

2023

  1. Current management of bowel failure due to Crohn's disease in Spain: Results of a GETECCU survey

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 6, pp. 439-445

  2. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  3. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  4. Influence of biologic therapy on cardiovascular risk factors in patients with inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 2, pp. 109-115

  5. Randomized clinical trial evaluating three low-volume preparations for colonoscopy in outpatients with Inflammatory Bowel Disease: the EII-PREP trial

    Scandinavian Journal of Gastroenterology, Vol. 58, Núm. 6, pp. 656-663

  6. Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study

    Revista Espanola de Enfermedades Digestivas, Vol. 115, Núm. 8, pp. 444-449

  7. Seroprevalence of ANTI-SARS-CoV-2 antibodies in patients with inflammatory bowel disease

    Scientific Reports, Vol. 13, Núm. 1

2022

  1. Correlation between endoscopy and intestinal ultrasound for the evaluation of postoperative recurrence of Crohn's disease

    Gastroenterologia y Hepatologia, Vol. 45, Núm. 1, pp. 40-46

  2. Nutricional habits in patients with inflammatory bowel disease: perception of patients and health professionals

    Gastroenterologia y Hepatologia, Vol. 45, pp. 2-3

2021

  1. Doppler Activity and Ultrasonographic Detection of Intra-Abdominal Fistulas Are Predictors of Surgery in Crohn's Disease

    Digestive Diseases, Vol. 39, Núm. 3, pp. 204-210

  2. Is the degree of i2a recurrence in Crohn's disease secondary to ischemic phenomena?

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 113, Núm. 4, pp. 246-250

  3. Optimization of azathioprine dose in combined treatment with anti-TNF-alpha in inflammatory bowel disease

    Gastroenterologia y Hepatologia, Vol. 44, Núm. 5, pp. 337-345

2020

  1. Management of COVID-19 Pandemic in Spanish Inflammatory Bowel Disease Units: Results From a National Survey

    Inflammatory bowel diseases, Vol. 26, Núm. 8, pp. 1149-1154

  2. Usefulness of monitoring antitumor necrosis factor serum levels during the induction phase in patients with Crohn's disease

    European Journal of Gastroenterology and Hepatology, Vol. 32, Núm. 5, pp. 588-596

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study

    Journal of Crohn's & colitis, Vol. 13, Núm. 12, pp. 1492-1500

  3. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

  4. Double-strand break repair through homologous recombination in autosomal-recessive BCL10 deficiency

    Journal of Allergy and Clinical Immunology, Vol. 143, Núm. 5, pp. 1931-1934.e1